5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular methylation and NAD+ metabolism. It is not a peptide, despite often appearing alongside peptides in research-chemical catalogues; it is a methylquinolinium compound developed through medicinal chemistry rather than solid-phase peptide synthesis. In the laboratory it is studied chiefly in rodent models of diet-induced obesity, muscle ageing and metabolic regulation, where NNMT inhibition is used as a tool to probe the role of cellular methylation capacity in adipose and muscle tissue. This article reviews its classification and structure, mechanism, the published preclinical literature, research applications and the handling requirements relevant to a laboratory setting.
What is 5-Amino-1MQ?
5-Amino-1MQ belongs to a class of quinolinium-derived small molecules rather than to any peptide family. Its 1-methylquinolinium scaffold is structurally related to 1-methylnicotinamide (1-MNA), the direct enzymatic product of NNMT, which is the basis for its mechanism of action as a substrate-competitive inhibitor. Research-grade material is typically supplied as a salt form, most often the iodide salt, since the parent compound in its neutral form is not stable in that way; suppliers should specify which salt form a given product represents, since this affects the mass of active compound per milligram of powder supplied.
The compound was developed and characterised by a research group at the University of Texas Health Science Center, with early structure-activity relationship work describing a series of quinolinium analogues optimised for selective, membrane-permeable NNMT inhibition. The lead compound from that programme, 5-amino-1MQ, was subsequently characterised pharmacologically and tested in cell and animal models, beginning with the foundational 2018 obesity study described below.
Mechanism of action
NNMT catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. Because SAM is the principal methyl donor used throughout cellular methylation reactions, including DNA and histone methylation, high NNMT activity is reported to deplete the cellular SAM pool and reduce nicotinamide’s availability for conversion, via the NAD+ salvage pathway, into nicotinamide mononucleotide and ultimately NAD+.
5-Amino-1MQ binds competitively at the NNMT substrate site, with reported selectivity for NNMT over related methyltransferases and NAD+ salvage pathway enzymes, including glycine N-methyltransferase, histamine N-methyltransferase, nicotinamide phosphoribosyltransferase and nicotinamide mononucleotide adenylyltransferase. By blocking nicotinamide methylation, the compound is reported to preserve more nicotinamide for the NAD+ salvage pathway and to spare SAM, which in adipocyte and muscle cell models has been linked to increased intracellular NAD+ and altered downstream signalling, including effects reported on sirtuin activity given SIRT1’s dependence on NAD+ as a cofactor.
In adipose tissue models, this shift toward preserved NAD+ and methylation capacity has been associated with suppressed lipogenic gene expression and reduced lipid accumulation in differentiating adipocytes. In skeletal muscle models, NNMT is reported to be upregulated with age and linked to impaired muscle stem cell function; inhibiting it is reported to support NAD+-dependent pathways relevant to muscle stem cell proliferation and differentiation. Because 5-Amino-1MQ acts on a metabolic enzyme rather than a cell-surface receptor, its effects in a given experimental system depend substantially on baseline NNMT expression in the tissue or cell type under study, which researchers should characterise before interpreting pharmacological results.
What the research shows
The foundational characterisation was reported by Neelakantan and colleagues in Biochemical Pharmacology in 2018. The study combined in vitro work in 3T3-L1 pre-adipocytes, where 5-Amino-1MQ produced concentration-dependent inhibition of lipid accumulation during differentiation, with an in vivo proof-of-concept study in diet-induced obese mice. Following an 11-day course of subcutaneous dosing, the treated mice showed a progressive reduction in body weight relative to controls, alongside reported reductions in white adipose tissue mass and adipocyte size (Neelakantan et al., 2018, PMC).
A related study by the same research group, published in Biochemical Pharmacology in 2019, examined skeletal muscle rather than adipose tissue, using an aged-mouse muscle injury model. The authors reported that NNMT inhibitor treatment enhanced proliferation and fusion of muscle stem cells and improved functional recovery of injured skeletal muscle in aged mice, with similar effects on myoblast differentiation reproduced in cultured C2C12 cells, alongside changes in NAD+/NADH-related cellular metabolites (Neelakantan et al., 2019, PMC).
Building on that muscle-ageing work, Dimet-Wiley and colleagues reported in Scientific Reports in 2024 a study comparing NNMT inhibitor treatment, structured exercise, and the combination of both in aged mice over a defined treatment period. The investigators reported that NNMT inhibitor-treated sedentary mice showed substantially greater grip strength than sedentary controls, that exercise alone produced a smaller improvement, and that the combination of NNMT inhibitor treatment and exercise produced the largest increase, with proteomic and metabolomic analyses used to investigate the underlying molecular changes in muscle tissue (Dimet-Wiley et al., 2024, PMC).
A separate line of published work has examined NNMT inhibition combined with dietary intervention in obese mice, reporting effects on body composition and the gut microbiome alongside the metabolic changes described above, extending the obesity-model findings beyond the original 11-day proof-of-concept study. Across all of these publications, doses, routes and treatment durations vary by research question, and none report data in human subjects; researchers needing specific protocol parameters should consult the primary methods sections rather than rely on a summary here.
Research applications
In the laboratory, 5-Amino-1MQ is used mainly as a pharmacological tool for probing NNMT’s role in cellular methylation and NAD+ metabolism. Adipocyte culture models, particularly 3T3-L1 cells during differentiation, are used to study lipogenesis, adipocyte size and NAD+-related metabolite changes in response to NNMT inhibition, often alongside NAD+ and SAM quantification assays to confirm target engagement.
Skeletal muscle research uses both cultured myoblast models, such as C2C12 cells, and rodent models of muscle injury or ageing, examining muscle stem cell proliferation, differentiation and functional recovery measures such as grip strength and contractile force following NNMT inhibitor treatment, frequently in comparison with or combination with structured exercise interventions, as in the studies described above.
Rodent models of diet-induced obesity remain a core application, used to study body weight, adiposity, glucose tolerance and related metabolic parameters following NNMT inhibition, either alone or alongside dietary interventions. Because NNMT expression and activity vary by tissue and by age, comparative studies across young and aged animals, and across adipose and muscle tissue, are a recurring feature of the published literature on this compound.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing 5-Amino-1MQ should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the target compound from synthesis by-products and confirms purity, with research-grade material commonly specified at 98% purity or above. Because 5-Amino-1MQ is typically supplied as a salt, mass spectrometry alongside HPLC helps confirm both compound identity and which salt form is present, since this affects the calculation of active compound concentration in any solution prepared from the powder. A batch-specific certificate of analysis, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected experimental data to be traced back to a defined lot.
The lyophilised or solid compound should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once dissolved in an appropriate solvent, such as water or DMSO depending on the intended assay, the solution should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk degradation and reduce reproducibility between experiments. Published stability data specific to reconstituted 5-Amino-1MQ are limited in the open literature, so laboratories should validate their own working window empirically, for example by comparing HPLC profiles of fresh and aged solutions and confirming activity in a relevant cell-based assay.
Frequently asked questions
What is 5-Amino-1MQ used for in research?
It is used mainly as a pharmacological tool for studying nicotinamide N-methyltransferase (NNMT) inhibition in rodent models of diet-induced obesity and in models of skeletal muscle ageing and regeneration, alongside cell culture work in adipocytes and myoblasts. It is not approved as a medicine, and this article makes no claims about use in humans.
Is 5-Amino-1MQ a peptide?
No. Despite being sold alongside peptides by some research-chemical suppliers, 5-Amino-1MQ is a small-molecule methylquinolinium compound, developed through conventional medicinal chemistry rather than peptide synthesis. It has no amino acid sequence, and its handling and analytical characterisation differ in some respects from those used for synthetic peptides.
What is the mechanism of action of 5-Amino-1MQ?
It is a substrate-competitive inhibitor of NNMT, an enzyme that methylates nicotinamide using S-adenosylmethionine as the methyl donor. By blocking this reaction, 5-Amino-1MQ is reported to preserve cellular SAM and increase nicotinamide availability for the NAD+ salvage pathway, raising intracellular NAD+ in adipocyte and muscle cell models studied to date.
How should 5-Amino-1MQ be stored once dissolved?
Dissolved 5-Amino-1MQ should be divided into single-use aliquots, kept refrigerated only briefly and otherwise frozen, protected from light, and not subjected to repeated freeze–thaw cycles. Because specific published stability data are limited, laboratories should confirm their own storage window empirically, for example by comparing HPLC profiles or assay activity of fresh and aged solutions.
The 5-Amino-1MQ discussed in this article is supplied for in-vitro and in-vivo laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
